Trial Profile
A Prospective, Randomized, Multicenter, Open-label Study of Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- 01 Oct 2021 Results (n=133) published in the Journal of Viral Hepatitis
- 21 Sep 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 21 Sep 2021 Planned primary completion date changed from 30 Dec 2020 to 30 Dec 2021.